Navigation Links
Promising Parkinson's Disease Research Highlighted by The Michael J. Fox Foundation to Accelerate Drug Development
Date:7/11/2013

NEW YORK, July 11, 2013 /PRNewswire-USNewswire/ -- Research projects from five biopharmaceutical companies in the United States, Canada and Israel comprise the 2013 first half (1H 2013) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program participants' research projects are presented directly to industry groups who may wish to invest in further development of the project. By connecting industry leaders with those studies ripe for investment, the Foundation aims to drive forward promising research in Parkinson's disease (PD) through the pipeline of drug development and eventually into patients' hands.

Non-confidential overviews of the selected MJFF-funded projects are shared with industry contacts and more broadly via MJFF's Web site twice yearly in July and December (previously quarterly).

Selected for the MJFF Partnering Program 1H 2013 are:

Disease-Modifying Research

  • Ceregene's clinical research on a gene delivery approach to neurotrophic factors (which can have a restorative effect on degenerating neurons) did not meet its primary endpoint, but saw some effects on secondary measures that suggest some benefits. Ceregene continues to analyze this data to identify areas for future research.
  • MedGenesis' investigation of GDNF, a biological neurotrophic factor and potential disease-modifying therapy. MedGenesis has in-licensed the product from Amgen and has developed an enhanced delivery paradigm to overcome previous limitations.
  • NeuroPhage Pharmaceuticals' study of NPT002, a potential disease-modifying therapy for PD that targets alpha-synuclein.  NPT002 binds, disaggregates and prevents the formation of multiple amyloidogenic structures. This novel approach has increased therapeutic potential as it targets both early amyloid assemblies as well as pre-existing aggregates.

Symptomatic Research

  • Cynapsus Therapeutics' development of APL-130277, a novel formulation of the drug apomorphine, as a rescue medication for intermittent OFF episodes in PD. APL-130277 is a thin film strip that dissolves under the tongue.
  • NeuroDerm's clinical research on continuous administration of levodopa and carbidopa through a "pump-patch." This technology could maintain continuous and constant concentration of levodopa in the blood, which should significantly decrease motor fluctuations and possibly reverse dyskinesia.

To date, the Foundation has funded $325 million in research, more than $84 million of which has been directed to over 185 unique projects led by industry partners.

For more information on the MJFF Partnering Program 1H 2013 participants and previously featured grantees, visit https://www.michaeljfox.org/research/opportunities-for-industry/partnering-program.html. The MJFF Research Partnerships team can be reached at ResearchPartnerships@michaeljfox.org.


'/>"/>
SOURCE The Michael J. Fox Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Adult and Adolescent Vaccines Market to 2018 Report - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
2. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
3. Novan Announces Promising Results of SB204 Clinical Study
4. International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
5. Use Of Cryoablation For Treatment Of Breast Cancer Shows Promising Results
6. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
7. University of Michigans Zell Lurie Institute Awards $112,000 to Promising Student Startups in 30th Annual Business Plan Competition and Dare to Dream Grant Program
8. Forbes Ranks SynCardia Among "Americas Most Promising Companies" for Second Straight Year
9. Meth Vaccine Shows Promising Results in Early Tests
10. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets
11. Boston Scientific Announces Promising Clinical Data on New Products at the International Spine Intervention Society 20th Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... 2016 , ... A revolution is underway. Brooklyn-based company, ... for the millions of people who require these medical transport services annually. ... the use of technology. Now, SmartEMS has put forth an industry-changing app that ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
Breaking Medicine News(10 mins):